<?xml version='1.0' encoding='utf-8'?>
<document id="31330406"><sentence text="Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies."><entity charOffset="18-26" id="DDI-PubMed.31330406.s1.e0" text="adefovir" /><entity charOffset="31-43" id="DDI-PubMed.31330406.s1.e1" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.31330406.s1.e0" e2="DDI-PubMed.31330406.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31330406.s1.e0" e2="DDI-PubMed.31330406.s1.e1" /></sentence><sentence text="As a tool to be used in transporter-mediated drug-drug interaction studies, a sensitive LC-MS/MS method for the simultaneous quantification of adefovir and pitavastatin in human plasma and adefovir in urine was developed and successfully validated"><entity charOffset="143-151" id="DDI-PubMed.31330406.s2.e0" text="adefovir" /><entity charOffset="156-168" id="DDI-PubMed.31330406.s2.e1" text="pitavastatin" /><entity charOffset="189-197" id="DDI-PubMed.31330406.s2.e2" text="adefovir" /><pair ddi="false" e1="DDI-PubMed.31330406.s2.e0" e2="DDI-PubMed.31330406.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31330406.s2.e0" e2="DDI-PubMed.31330406.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31330406.s2.e0" e2="DDI-PubMed.31330406.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31330406.s2.e1" e2="DDI-PubMed.31330406.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31330406.s2.e1" e2="DDI-PubMed.31330406.s2.e2" /></sentence><sentence text=" Plasma samples were processed by protein precipitation using methanol with a subsequent concentrating step"><entity charOffset="62-70" id="DDI-PubMed.31330406.s3.e0" text="methanol" /></sentence><sentence text=" Urine samples were diluted using 0" /><sentence text="1% formic acid"><entity charOffset="3-14" id="DDI-PubMed.31330406.s5.e0" text="formic acid" /></sentence><sentence text=" Separation was achieved on a Synergy Polar-RP reversed phase column (50 × 4" /><sentence text="6 mm, 2" /><sentence text="5 μm) in gradient elution using a mobile phase composed of water and 0" /><sentence text="1% formic acid and a mixture of methanol and acetonitrile (50:50, v/v) containing 0"><entity charOffset="3-14" id="DDI-PubMed.31330406.s9.e0" text="formic acid" /><entity charOffset="32-40" id="DDI-PubMed.31330406.s9.e1" text="methanol" /><entity charOffset="45-57" id="DDI-PubMed.31330406.s9.e2" text="acetonitrile" /><pair ddi="false" e1="DDI-PubMed.31330406.s9.e0" e2="DDI-PubMed.31330406.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31330406.s9.e0" e2="DDI-PubMed.31330406.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31330406.s9.e0" e2="DDI-PubMed.31330406.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31330406.s9.e1" e2="DDI-PubMed.31330406.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31330406.s9.e1" e2="DDI-PubMed.31330406.s9.e2" /></sentence><sentence text="1% formic acid at a flow rate of 1"><entity charOffset="3-14" id="DDI-PubMed.31330406.s10.e0" text="formic acid" /></sentence><sentence text="0 mL/min" /><sentence text=" The linear range covered concentrations from 0" /><sentence text="273 to 52" /><sentence text="6 ng/mL for adefovir and from 0"><entity charOffset="12-20" id="DDI-PubMed.31330406.s14.e0" text="adefovir" /></sentence><sentence text="539 to 104" /><sentence text="2 ng/mL for pitavastatin in human plasma, respectively"><entity charOffset="12-24" id="DDI-PubMed.31330406.s16.e0" text="pitavastatin" /></sentence><sentence text=" The calibration curve for adefovir in urine ranged from 0"><entity charOffset="27-35" id="DDI-PubMed.31330406.s17.e0" text="adefovir" /></sentence><sentence text="104 to 10" /><sentence text="0 μg/mL" /><sentence text=" The weighted linear regression (1/conc2) implied excellent linearity with correlation coefficients ≥0" /><sentence text="999" /><sentence text="" /></document>